Taking everything into account, AGIO scores 4 out of 10 in our fundamental rating. AGIO was compared to 525 industry peers in the Biotechnology industry. AGIO has a great financial health rating, but its profitability evaluates not so good. AGIO is valied quite expensively at the moment, while it does show a decent growth rate.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.96% | ||
| ROE | -31.24% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 87.22% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.8 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.82 | ||
| Quick Ratio | 13.39 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ChartMill assigns a fundamental rating of 4 / 10 to AGIO.
ChartMill assigns a valuation rating of 0 / 10 to AGIOS PHARMACEUTICALS INC (AGIO). This can be considered as Overvalued.
AGIOS PHARMACEUTICALS INC (AGIO) has a profitability rating of 2 / 10.